OSR Health (OSRHW) Accounts Payables (2021 - 2026)
OSR Health (OSRHW) posted Accounts Payables of $8.3 million for Q1 2026, up 5.52% sequentially from $7.8 million in Q4 2025, and up 13.24% YoY from $7.3 million in Q1 2025.
OSR Health (OSRHW) Accounts Payables (2021 - 2026) Analysis & Trends
OSR Health has reported Accounts Payables for 6 years, with the latest figure at $8.3 million in Q1 2026.
- Quarterly Accounts Payables rose 13.24% year-over-year to $8.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $8.3 million (up 13.24% YoY) and the FY2025 annual result came in at $7.8 million, up 625.84% from the prior year.
- Accounts Payables rose to $8.3 million in Q1 2026 per OSRHW's latest filing, from $7.8 million in the prior quarter.
- Over five years, Accounts Payables peaked at $8.3 million in Q1 2026 and troughed at $34000.0 in Q4 2022.
- A 5-year average of $3.3 million and a median of $1.2 million in 2023 frame the typical range for Accounts Payables.
- The sharpest annual moves came in 2023 and 2024: Accounts Payables surged 3081.63% in 2023, then retreated 0.28% in 2024.
- Over 5 years, Accounts Payables stood at $34000.0 in 2022, then soared by 3081.63% to $1.1 million in 2023, then decreased by 0.28% to $1.1 million in 2024, then surged by 625.84% to $7.8 million in 2025, then grew by 5.52% to $8.3 million in 2026.
- According to Business Quant data, Accounts Payables over the past three periods registered $8.3 million, $7.8 million, and $7.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.97 Bn | 131.12 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.15 Bn | 77.15 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 62.84 Bn | 57.65 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 55.74 Bn | 50.60 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.53 Bn | 36.43 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.60 Bn | 28.29 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 27.32 Bn | 8.93 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Royalty Pharma | 27.29 Bn | 26.45 Bn | - | 35.57 Mn |
| 9 | Insmed | 26.99 Bn | 25.83 Bn | 358.27 Mn | 428.93 Mn |
| 10 | OSR Health | 1.40 Mn | 20.39 Mn | 86,605.00 | 8.01 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 8.26 Mn |
| Dec 31, 2025 | 7.83 Mn |
| Sep 30, 2025 | 7.66 Mn |
| Jun 30, 2025 | 7.56 Mn |
| Mar 31, 2025 | 7.30 Mn |
| Dec 31, 2024 | 1.08 Mn |
| Sep 30, 2024 | 1.26 Mn |
| Jun 30, 2024 | 1.05 Mn |
| Mar 31, 2024 | 1.55 Mn |
| Dec 31, 2023 | 1.08 Mn |
| Sep 30, 2023 | 500,354.00 |
| Jun 30, 2023 | 266,485.00 |
| Mar 31, 2023 | 386,432.00 |
| Dec 31, 2022 | 34,000.00 |
| Dec 31, 2021 | 2,847.00 |